Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (eBook, ePUB)

Redaktion: Faber, Anthony

• Format: ePub

Produktbeschreibung

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.

This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.

• Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented
• Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors
• Encompasses the current state of affairs in clinical trials to address resistance

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 150
• Erscheinungstermin: 30. Januar 2023
• Englisch
• ISBN-13: 9780128228340
• Artikelnr.: 67376929

Inhaltsangabe

1. The EGFR in NSCLC: Biology, activation and targeting2. Background of the
EGFR receptor, biology of activation, regulation of EGFR in normal cells
and cancer cells, mutations as oncogenic in NSCLC3. Background of EGFR
inhibitor development and implementation, assessment of how EGFR inhibitors
have been implemented and are currently implemented4. YAP signalling in
EGFR inhibitor resistance5. Apoptosis resistance in EGFR inhibitor
resistance6. EGFR mutations and resistance to EGFR inhibitors7. SCLC
transformation and resistance to EGFR inhibitors8. EMT and resistance to
EGFR inhibitors in EGFR mutant NSCLC9. Intratumoral heterogeneity and
resistance10. Clinical trials of EGFR inhibitors in EGFR mutant lung
cancer11. Methodology of the detection of resistant mechanisms in the lung
cancer clinic